Literature DB >> 33947745

Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.

Joseph L Sottnik1, Evelyn K Bordeaux1, Sanjana Mehrotra1, Sarah E Ferrara2, Andrew E Goodspeed2,3, James C Costello2,3, Matthew J Sikora4.   

Abstract

Invasive lobular carcinoma (ILC) is the most common special histologic subtype of breast cancer, and nearly all ILC tumors express estrogen receptor alpha (ER). However, clinical and laboratory data suggest ILC are strongly estrogen-driven but not equally antiestrogen-sensitive. We hypothesized ILC-specific ER coregulators mediate ER functions and antiestrogen resistance in ILC, and profiled ER-associated proteins by mass spectrometry. Three ER+ ILC cell lines (MDA MB 134VI, SUM44PE, and BCK4) were compared with ER+ invasive ductal carcinoma (IDC) line data, and we examined whether siRNA of identified proteins suppressed ER-driven proliferation in ILC cells. This identified mediator of DNA damage checkpoint 1 (MDC1), a tumor suppressor in DNA damage response (DDR), as a novel ER coregulator in ILC. We confirmed ER:MDC1 interaction was specific to ILC versus IDC cells, and found MDC1 knockdown suppressed ILC cell proliferation and tamoxifen resistance. Using RNA-sequencing, we found in ILC cells MDC1 knockdown broadly dysregulates the ER transcriptome, with ER:MDC1 target genes enriched for promoter hormone response elements. Importantly, our data are inconsistent with MDC1 tumor suppressor functions in DDR, but suggest a novel oncogenic role for MDC1 as an ER coregulator. Supporting this, in breast tumor tissue microarrays, MDC1 protein was frequently low or absent in IDC, but MDC1 loss was rare in ER+ ILC. ER:MDC1 interaction and MDC1 coregulator functions may underlie ER function in ILC and serve as targets to overcome antiestrogen resistance in ILC. IMPLICATIONS: MDC1 has novel ER coregulator activity in ILC, which may underlie ILC-specific ER functions, estrogen response, and antiestrogen resistance. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33947745      PMCID: PMC8349796          DOI: 10.1158/1541-7786.MCR-21-0025

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  48 in total

1.  MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals.

Authors:  Zhenkun Lou; Katherine Minter-Dykhouse; Sonia Franco; Monica Gostissa; Melissa A Rivera; Arkady Celeste; John P Manis; Jan van Deursen; André Nussenzweig; Tanya T Paull; Frederick W Alt; Junjie Chen
Journal:  Mol Cell       Date:  2006-01-20       Impact factor: 17.970

2.  Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy.

Authors:  Akshar N Patel; Sharad Goyal; Hao Wu; Devora Schiff; Meena S Moran; Bruce G Haffty
Journal:  Breast Cancer Res Treat       Date:  2010-06-03       Impact factor: 4.872

3.  Outcome of special types of luminal breast cancer.

Authors:  M Colleoni; N Rotmensz; P Maisonneuve; M G Mastropasqua; A Luini; P Veronesi; M Intra; E Montagna; G Cancello; A Cardillo; M Mazza; G Perri; M Iorfida; G Pruneri; A Goldhirsch; G Viale
Journal:  Ann Oncol       Date:  2011-10-29       Impact factor: 32.976

4.  Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Authors:  Ganesh V Raj; Gangadhara Reddy Sareddy; Shihong Ma; Tae-Kyung Lee; Suryavathi Viswanadhapalli; Rui Li; Xihui Liu; Shino Murakami; Chien-Cheng Chen; Wan-Ru Lee; Monica Mann; Samaya Rajeshwari Krishnan; Bikash Manandhar; Vijay K Gonugunta; Douglas Strand; Rajeshwar Rao Tekmal; Jung-Mo Ahn; Ratna K Vadlamudi
Journal:  Elife       Date:  2017-08-08       Impact factor: 8.140

5.  Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

Authors:  Bernhard C Pestalozzi; David Zahrieh; Elizabeth Mallon; Barry A Gusterson; Karen N Price; Richard D Gelber; Stig B Holmberg; Jurij Lindtner; Raymond Snyder; Beat Thürlimann; Elizabeth Murray; Giuseppe Viale; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

6.  Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

Authors:  Otto Metzger Filho; Anita Giobbie-Hurder; Elizabeth Mallon; Barry Gusterson; Giuseppe Viale; Eric P Winer; Beat Thürlimann; Richard D Gelber; Marco Colleoni; Bent Ejlertsen; Marc Debled; Karen N Price; Meredith M Regan; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2015-07-27       Impact factor: 44.544

7.  MDC1 PST-repeat region promotes histone H2AX-independent chromatin association and DNA damage tolerance.

Authors:  Israel Salguero; Rimma Belotserkovskaya; Julia Coates; Matylda Sczaniecka-Clift; Mukerrem Demir; Satpal Jhujh; Marcus D Wilson; Stephen P Jackson
Journal:  Nat Commun       Date:  2019-11-15       Impact factor: 14.919

8.  MDC1 Enhances Estrogen Receptor-mediated Transactivation and Contributes to Breast Cancer Suppression.

Authors:  Renlong Zou; Xinping Zhong; Chunyu Wang; Hongmiao Sun; Shengli Wang; Lin Lin; Shiying Sun; Changci Tong; Hao Luo; Peng Gao; Yanshu Li; Tingting Zhou; Da Li; Liu Cao; Yue Zhao
Journal:  Int J Biol Sci       Date:  2015-07-03       Impact factor: 6.580

9.  WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.

Authors:  Matthew J Sikora; Britta M Jacobsen; Kevin Levine; Jian Chen; Nancy E Davidson; Adrian V Lee; Caroline M Alexander; Steffi Oesterreich
Journal:  Breast Cancer Res       Date:  2016-09-20       Impact factor: 6.466

10.  Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4.

Authors:  Madeleine T Shackleford; Deviyani M Rao; Evelyn K Bordeaux; Hannah M Hicks; Christina G Towers; Joseph L Sottnik; Steffi Oesterreich; Matthew J Sikora
Journal:  Cancers (Basel)       Date:  2020-10-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.